SCHEMBL27207166

SCHEMBL27207166

CC(=O)OC(C)CCCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.48
PKM P14618 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MAOB P27338 4/20 0.47
MAPT P10636 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HDAC1 Q13547 4/20 0.46
HDAC7 Q8WUI4 4/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46
HDAC5 Q9UQL6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27203457 1.00 NPC1 (0.48) NPC1PKMMEN1KMT2AHSD17B10
SCHEMBL21694484 0.84 MEN1 (0.43) NPC1MEN1KMT2AHSD17B10MAOB
SCHEMBL16474055 0.82 MAPT (0.51) MEN1KMT2AMAOBMAPTRAB9A
SCHEMBL19985874 0.79 MAOB (0.49) MAOBMAPTRAB9ASMN1; SMN2
SCHEMBL30956213 0.79 NPC1 (0.43) NPC1PKMMEN1KMT2AHSD17B10
SCHEMBL17267600 0.79 HDAC7 (0.57) KMT2AMAOBMAPTRAB9ASMN1; SMN2
SCHEMBL17267469 0.79 HDAC7 (0.57) KMT2AMAOBMAPTRAB9ASMN1; SMN2
SCHEMBL17267471 0.79 HDAC7 (0.57) KMT2AMAOBMAPTRAB9ASMN1; SMN2
SCHEMBL29740550 0.79 CHRM2 (0.57) MEN1KMT2AMAOB
SCHEMBL20472107 0.79 CHRM2 (0.57) MEN1KMT2AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132517-A1 MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF GOHARMONY THERAPEUTICS (SHENZHEN) CO., LTD. (CN) 2024-04-25 US disclosed
WO-2022171139-A1 MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF 北京国鸿生物医药科技有限公司 2022-08-18 WO disclosed
CN-110950890-B Substituted imidazo [4,5-c ] quinoline macrocycles as multi-target kinase inhibitors 北京赛林泰医药技术有限公司 2022-07-01 CN disclosed
CN-110950890-A Substituted imidazo [4,5-c ] quinoline macrocycles as multi-target kinase inhibitors 北京赛林泰医药技术有限公司 2020-04-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132517-A1 MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF SRC, FLT3, BRAF NPC1 778/4885PKM 125/4885MEN1 756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.